Vaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company
This first-in-human, dose-escalation Phase 1 trial evaluates the safety, tolerability, and immunogenicity of VXCO-102 in healthy young adults across multiple sites in Australia.
The trial will enroll up to 90 participants aged 18-25. After sentinel safety review in each dose cohort, participants will be randomized to receive VXCO-102 or placebo, with a booster at Week 8.
All participants will undergo ongoing safety monitoring and immune response assessments through clinical evaluations, sample collection, and participant reporting.
Age
18–25
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Aged 18 to 25 years, inclusive
Healthy per medical assessment based on self-reported medical history, physical examination, vital signs, and laboratory assessment
You may not be if
Self-reported or medically-documented significant medical or psychiatric condition that per medical assessment could interfere with study participation
Likely or confirmed myocarditis or pericarditis
Prior receipt of an investigational EBV vaccine
Prior receipt of a licensed vaccine within 56 days prior to Day 1
Received more than 10 days of any systemic immunosuppressants or cytotoxic medications within 56 days prior to Day 1, any within 14 days prior to Day 1, or will need immunosuppressants at any time during the study.
For participants of childbearing potential: pregnant, breastfeeding or planning to become pregnant during the study